【摘要】 本研究分析难治/复发髓系白血病行脐带间充质干细胞(UC-MSC)联合单倍体相合异基因造血干细胞(haplo-HSCT)移植的临床疗效。回顾性总结2007年1月-2013年6月完成的36例难治/复发髓系白血病患者进行UC-MSC联合haplo-HSCT移植后的资料,分析移植后细胞植入、移植物抗宿主病发生率及其严重程度和2年总生存情况。结果表明,36例患者白细胞和血小板植入时间分别为12 d及14 d,Ⅲ-Ⅳ度aGVHD发生率为13.8%,cGVHD发生率为37.5%,广泛性cGVHD仅为6.25%,2年总生存为76.9%。结论:UC-MSC联合haplo-HSCT移植对难治/复发髓系白血病患者具有良好疗效,是用于有高危因素和无全相合供者患者治疗方法之一。更多还原

【Abstract】 This study was purposed to analyse the clinical efficacy of transplantation of umbilical cord mesenchymal stem cells( UC-MSC) combined with haploidentical hematopoietic stem cells( haplo-HSCT) for patients with refractory /relapsed myeloid leukemia. The clinical data of 36 patients received transplantation of UC-MSC combined with haplo-HSCT from January 2007 to June 2013 were summarized retrospectively,the engraftment,GVHD and 2yeari-overall survival(OS) were analysed. The results showed that the median times of neutrophil count > 0. 50 × 109/L and platelet count > 20 × 109/L were 12. 0 days and 14. 0 days,respectively. Grade Ⅲ to Ⅳ aGVHD occurred in 5 out of 36 patients(13. 8%). cGVHD occurred in 12 out of 32 patients(37. 5%) and extensive cGVHD occurred in 2patients. Additionally,only 3 patients(8. 3%) experienced relapse. The 2-year OS rate of patients was 76. 9%. It is concluded that the transplantation of UC-MSC combined with haplo-HSCT has good therapeutic efficacy for patients with refractory /relapsed myeloid leukemia,and may be served as a therapeutic method especially for patients with high risk and without well matched donor.更多还原